{"id":"treament-c","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"73d937da-efa9-4095-84ea-4eeeab119546","title":"TAGRID ANTIFUNGAL KIT (TOLNAFTATE,CLOTRIMAZOLE) KIT [TAGRID LLC]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to a reduction in the production of a key molecule involved in the disease process. As a result, the drug helps to alleviate symptoms and slow disease progression.","oneSentence":"Treatment C works by inhibiting the activity of a specific enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:11:00.314Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06192966","phase":"NA","title":"Effect of Probiotics on Recurrent Urinary Tract Infections","status":"TERMINATED","sponsor":"AB Biotics, SA","startDate":"2018-01-01","conditions":"Urinary Tract Infections","enrollment":106},{"nctId":"NCT01534819","phase":"","title":"ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medtronic Cardiovascular","startDate":"2012-04","conditions":"Aortic Aneurysm","enrollment":1090},{"nctId":"NCT06732557","phase":"NA","title":"Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-12","conditions":"Forward Head Posture","enrollment":60},{"nctId":"NCT04526795","phase":"PHASE1","title":"Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-09","conditions":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia","enrollment":19},{"nctId":"NCT04489134","phase":"PHASE2","title":"P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2022-02-15","conditions":"Pharmacokinetics","enrollment":27},{"nctId":"NCT04210583","phase":"NA","title":"RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity","status":"COMPLETED","sponsor":"Venus Concept","startDate":"2019-09-04","conditions":"Vulvovaginal Atrophy, Menopause, Menopause Surgical","enrollment":10},{"nctId":"NCT05690490","phase":"NA","title":"Endoscopic Mucosal Resection With Circumferential Incision for Colorectal Neoplasms","status":"UNKNOWN","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2020-11-27","conditions":"Endoscopic Mucosal Resection With Circumferential Incision","enrollment":90},{"nctId":"NCT00701389","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-20","conditions":"Migraine Disorders","enrollment":24},{"nctId":"NCT01627587","phase":"PHASE1","title":"A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-12","conditions":"Obstetric Labour, Premature","enrollment":46},{"nctId":"NCT01805882","phase":"PHASE2","title":"Combination Therapy for Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-01","conditions":"Hepatitis C, Chronic","enrollment":229}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Treament C","genericName":"Treament C","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treatment C, also known as telcagepant, is a small molecule used in clinical trials for various conditions, including Migraine Disorders, Hepatitis C, and Aortic Aneurysm. It has been studied in combination with sumatriptan for the treatment of migraine patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}